About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Small Molecules
  Branded Formulations
  Research Services



Biocon provides CytoSorb®, a novel therapy for the management of sepsis, in India. Inflammation generated during cardiac surgery and cardiopulmonary bypass can lead to post-operative inflammation and adverse outcomes, including lung and kidney failure. The use of CytoSorb® intra-operatively in a bypass circuit in the heart-lung machine is designed to remove inflammatory substances and reduce post-operative complications. Under the expanded partnership, Biocon will leverage its cardiac care commercial capabilities to now promote CytoSorb® for treating harmful, excess inflammation associated with cardiac surgery.

CytoSorb® is a safe and effective extracorporeal cytokine filter, designed to target the prevention or treatment of organ failure which is the cause of nearly half of all deaths in the intensive care unit. If left unchecked, 'cytokine storm' caused by excessive cytokine production can cause massive inflammation, organ failure and death in common life-threatening conditions such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb® has CE Mark regulatory approval, and is clinically proven to control cytokine storm in critically-ill patients by reducing key cytokines in blood by 30-50%. It also works easily with standard dialysis machines used in hospitals.

Physicians and Health Care Professionals has enthusiastically embraced CytoSorb® as a safe and well tolerated therapy for managing sepsis.

The effective treatment of sepsis needs to address two components - the infection and the over-activation of the immune system. By combining Biocon’s critical care antibiotics to treat the infection that are also compatible with CytoSorb® therapy to modulate the immune response, the two companies are providing the most comprehensive solution for sepsis management.

Severe sepsis and septic shock are major causes of morbidity and mortality worldwide. It is a leading cause of death in non-coronary ICUs and the 11th leading cause of death overall. Over a third of patients who develop sepsis die globally, even when the best standard of care is available. In India, more than one million estimated new cases of severe sepsis are treated in the Indian ICUs each year, accounting for one out of every four patients in the ICU.

 Patient Contact
Comprehensive Care, Biocon
 Dr. Vikram Shetty 
 M: +91 88840 00371
 Mr. Pradeep Y
  M: +91 88840 00371
 T: +91 80 6775 1315


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved